



December 9, 2024

PeptiDream Inc
<https://www.peptidream.com/en/>
(Securities Code: 4587 TSE Prime Market)

PeptiDream Announces Upcoming Presentation of Ph0 Human Imaging Study Results for ⁶⁴Cu-PD-32766, CA9-Targeting PD-32766 Program at ASCO Genitourinary Cancers Symposium

KANAGAWA, JAPAN – December 9, 2024 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) announced that the company will be presenting the results of its recently completed Ph0 first-in-human imaging study of its ⁶⁴Cu-PD-32766 program targeting Carbonic Anhydrase IX (“CA9”) as a potential targeted radiotherapy and radiodiagnostic for clear cell renal cell carcinoma (“ccRCC”) at the American Society of Clinical Oncology’s (“ASCO”) Genitourinary Cancers Symposium (“ASCO-GU 2025”) to be held in San Francisco, California from February 13-15, 2025.

CA9 is a cell surface antigen highly expressed in ~95% of ccRCC patients with minimal expression in normal tissues. PeptiDream is currently developing PD-32766 as both a radiotherapeutic (labeled with the radionuclide Actinium225; “²²⁵Ac”) and a radiodiagnostic (labeled with the radionuclide Copper 64; “⁶⁴Cu”) imaging agent for the potential treatment and diagnosis of ccRCC. The human imaging Ph0 study results of ⁶⁴Cu-PD-32766 in patients with ccRCC will be presented.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com